Study looks at factor VIII products for hemophilia A

01/17/2013 | PhysiciansBriefing.com

The odds of inhibitory antibody development were the same for children with hemophilia A who took plasma-derived factor VIII products and those in the recombinant group, a Dutch study found. Researchers reported in the New England Journal of Medicine that inhibitor development risk was not linked with the von Willebrand factor content of these products or with switching between plasma-derived and recombinant.

View Full Article in:

PhysiciansBriefing.com

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA